Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades5
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge
1 Nov 2019 - Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee
9 Oct 2019 - Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study
9 Oct 2019 - Faron Pharmaceuticals hits bump in road for Traumakine manufacturing
2 Oct 2019 - Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals
2 Oct 2019 - Faron Pharmaceuticals Ends Traumakine Trial; Loss Narrows On Expenses
23 Sep 2019 - UK Earnings, Trading Statements Calendar - Next 7 Days
16 Sep 2019 - Faron Pharma raises ?2.3m to keep it going through the start of 2020
27 Aug 2019
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge
Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge
Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee...
Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study
Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study
Faron Pharmaceuticals hits bump in road for Traumakine manufacturing
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim re...
Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals
Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals
Faron Pharmaceuticals Ends Traumakine Trial; Loss Narrows On Expenses
(Alliance News) - Faron Pharmaceuticals Oy on Monday said its loss narrowed considerably in the first half of 2019, after it cut back on research & de...
UK Earnings, Trading Statements Calendar - Next 7 Days
Tuesday 17 September JTCHalf Year ResultsStafflineHalf Year GroupHalf Year Year
Faron Pharma raises ?2.3m to keep it going through the start of 2020
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has received valid acceptances and excess applications from qualifyi...
Follow the stocks
